Literature DB >> 31488618

Pediatric NUT Carcinoma Is a Rare and Challenging Tumor: Single Center Experience of Five Children.

Maya Prasad1,2, Akshay Baheti3,2, Mukta Ramadwar4,2, Girish Chinnaswamy5,2, Tushar Vora5,2, Sajid Qureshi6,2.   

Abstract

BACKGROUND: Nuclear protein of the testis (NUT) carcinoma is a rare and aggressive malignancy associated with rearrangements of the nuclear protein of the testis (NUT) gene on chromosome 15q14. Because of its rarity, this tumor is often underdiagnosed and underreported, and there is limited literature regarding its biology and optimal management. METHODS AND
RESULTS: We report our experience of five patients with pediatric NUT carcinoma, all of whom presented with midline head and neck mass. In spite of aggressive multimodality treatment, only one patient survives.
CONCLUSION: NUT carcinoma has a dismal prognosis in spite of aggressive multimodality management (surgery and adjuvant chemotherapy and/or radiation). Novel strategies are required to improve outcomes of patients with this tumor. © AlphaMed Press 2019.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31488618      PMCID： PMC6853094          DOI： 10.1634/theoncologist.2019-0358

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  12 in total

1.  Differentiation of NUT midline carcinoma by epigenomic reprogramming.

Authors:  Brian E Schwartz; Matthias D Hofer; Madeleine E Lemieux; Daniel E Bauer; Michael J Cameron; Nathan H West; Elin S Agoston; Nicolas Reynoird; Saadi Khochbin; Tan A Ince; Amanda Christie; Katherine A Janeway; Sara O Vargas; Antonio R Perez-Atayde; Jon C Aster; Stephen E Sallan; Andrew L Kung; James E Bradner; Christopher A French
Journal:  Cancer Res       Date:  2011-03-29       Impact factor: 12.701

2.  Clinicopathologic features and long-term outcomes of NUT midline carcinoma.

Authors:  Daniel E Bauer; Chelsey M Mitchell; Kelly M Strait; Christopher S Lathan; Edward B Stelow; Sonja C Lüer; Somala Muhammed; Andrew G Evans; Lynette M Sholl; Juan Rosai; Eugenia Giraldi; Richard P Oakley; Carlos Rodriguez-Galindo; Wendy B London; Stephen E Sallan; James E Bradner; Christopher A French
Journal:  Clin Cancer Res       Date:  2012-08-15       Impact factor: 12.531

3.  Pediatric NUT-midline carcinoma: Therapeutic success employing a sarcoma based multimodal approach.

Authors:  Simone Storck; Alyssa L Kennedy; Karen J Marcus; Lisa Teot; Jennifer Vaughn; Astrid K Gnekow; Bruno Märkl; Ivo Leuschner; Steven G DuBois; Christopher A French; Michael C Frühwald
Journal:  Pediatr Hematol Oncol       Date:  2017-10-17       Impact factor: 1.969

4.  Histone deacetylase inhibitor for NUT midline carcinoma.

Authors:  Ossama M Maher; Anthony M Christensen; Sireesha Yedururi; Diana Bell; Nidale Tarek
Journal:  Pediatr Blood Cancer       Date:  2015-01-03       Impact factor: 3.167

Review 5.  NUT midline carcinoma.

Authors:  Christopher Alexander French
Journal:  Cancer Genet Cytogenet       Date:  2010-11

6.  NUT carcinoma in children and adults: A multicenter retrospective study.

Authors:  Lauriane Lemelle; Gaëlle Pierron; Paul Fréneaux; Sophie Huybrechts; Alexandra Spiegel; Dominique Plantaz; Morbize Julieron; Sophie Dumoucel; Antoine Italiano; Fréderic Millot; Christophe Le Tourneau; Guy Leverger; Pascal Chastagner; Matthieu Carton; Daniel Orbach
Journal:  Pediatr Blood Cancer       Date:  2017-06-23       Impact factor: 3.167

7.  Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck.

Authors:  Nicole G Chau; Shelley Hurwitz; Chelsey M Mitchell; Alexandra Aserlind; Noam Grunfeld; Leah Kaplan; Peter Hsi; Daniel E Bauer; Christopher S Lathan; Carlos Rodriguez-Galindo; Roy B Tishler; Robert I Haddad; Stephen E Sallan; James E Bradner; Christopher A French
Journal:  Cancer       Date:  2016-08-10       Impact factor: 6.860

8.  NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism.

Authors:  Christopher A French; Shaila Rahman; Erica M Walsh; Simone Kühnle; Adlai R Grayson; Madeleine E Lemieux; Noam Grunfeld; Brian P Rubin; Cristina R Antonescu; Songlin Zhang; Rajkumar Venkatramani; Paola Dal Cin; Peter M Howley
Journal:  Cancer Discov       Date:  2014-05-29       Impact factor: 39.397

9.  Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody.

Authors:  Herbert Haack; Laura A Johnson; Christopher J Fry; Katherine Crosby; Roberto D Polakiewicz; Edward B Stelow; Seung-Mo Hong; Brian E Schwartz; Michael J Cameron; Mark A Rubin; Martin C Chang; Jon C Aster; Christopher A French
Journal:  Am J Surg Pathol       Date:  2009-07       Impact factor: 6.394

10.  Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinoma-an aggressive and fatal disease.

Authors:  Anja Stirnweiss; Joyce Oommen; Rishi S Kotecha; Ursula R Kees; Alex H Beesley
Journal:  Oncotarget       Date:  2017-12-02
View more
  3 in total

1.  NUT Carcinoma Without Upfront Surgical Resection: A Case Report.

Authors:  Rachel Leeman; Kerice Pinkney; Julie A Bradley; Robert Ruiz; Steven G DuBois; Christopher French; Matteo Trucco
Journal:  J Pediatr Hematol Oncol       Date:  2021-07-01       Impact factor: 1.170

2.  Complete Response Induced by Concurrent Chemoradiotherapy in a Patient with NUT Carcinoma.

Authors:  Joji Muramatsu; Kohichi Takada; Shintaro Sugita; Takaaki Tsuchiya; Keisuke Yamamoto; Masaru Takagi; Kazuyuki Murase; Saki Ameda; Yohei Arihara; Koji Miyanishi; Koh-Ichi Sakata; Junji Kato
Journal:  Intern Med       Date:  2021-10-05       Impact factor: 1.282

Review 3.  NUT Carcinoma-An Underdiagnosed Malignancy.

Authors:  Ulrich M Lauer; Martina Hinterleitner; Marius Horger; Paul V Ohnesorge; Lars Zender
Journal:  Front Oncol       Date:  2022-07-26       Impact factor: 5.738
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.